{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:18:49Z","timestamp":1790313529570,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Ascendis Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03396-0","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:50:33Z","timestamp":1761299433000},"page":"6234-6247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA)"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-0694","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"D\u00edez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Badia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Alerany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Climente Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mu\u00f1oz Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"3396_CR1","doi-asserted-by":"crossref","unstructured":"Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L, et al. European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur J Endocrinol. [Internet]. 2022 [cited 2024 Oct 2];186(2):R33\u201363. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34863037\/","DOI":"10.1530\/EJE-21-1044"},{"key":"3396_CR2","doi-asserted-by":"crossref","unstructured":"Mannstadt M, Bilezikian JP, Thakker R V., Hannan FM, Clarke BL, Rejnmark L, et al. Hypoparathyroidism. Nat Rev Dis Primers. 2017 3:1 [Internet]. 2017 [cited 2024 Oct 21];3(1):1\u201321. Available from: https:\/\/www.nature.com\/articles\/nrdp201755","DOI":"10.1038\/nrdp.2017.80"},{"issue":"4","key":"3396_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ecl.2018.07.004","volume":"47","author":"BL Clarke","year":"2018","unstructured":"Clarke BL. Epidemiology and complications of hypoparathyroidism. Endocrinol Metab Clin North Am. 2018;47(4):771\u201382.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3396_CR4","unstructured":"(EMA) EMA. Yorvipath EPAR [Internet]. [cited 2024 Oct 8]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yorvipath"},{"issue":"2","key":"3396_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cen.14128","volume":"92","author":"H Siggelkow","year":"2020","unstructured":"Siggelkow H, Clarke BL, Germak J, Marelli C, Chen K, Dahl-Hansen H, et al. Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13-country patient and caregiver survey. Clin Endocrinol (Oxf). 2020;92(2):159\u201368. https:\/\/doi.org\/10.1111\/cen.14128.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"3396_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/13696998.2019.1624081","volume":"22","author":"K Chen","year":"2019","unstructured":"Chen K, Krasner A, Li N, Xiang CQ, Totev T, Xie J. Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review. J Med Econ. 2019;22(11):1141\u201352. https:\/\/doi.org\/10.1080\/13696998.2019.1624081.","journal-title":"J Med Econ"},{"key":"3396_CR7","doi-asserted-by":"crossref","unstructured":"Brod M, Waldman LT, Smith A, Karpf D. Assessing the patient experience of hypoparathyroidism symptoms: development of the hypoparathyroidism patient experience scale-symptom (HPES-Symptom). Patient [Internet]. 2020 [cited 2025 Jan 23];13(2):151\u201362. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31552607\/","DOI":"10.1007\/s40271-019-00388-5"},{"key":"3396_CR8","doi-asserted-by":"crossref","unstructured":"Hadker N, Egan J, Sanders J, Lagast H, Clarke BL. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. Endocr Pract. [Internet]. 2014 [cited 2025 Jan 23];20(7):671\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24449664\/","DOI":"10.4158\/EP13328.OR"},{"issue":"12","key":"3396_CR9","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1002\/jbmr.4691","volume":"37","author":"AA Khan","year":"2022","unstructured":"Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL, et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop. J Bone Miner Res. 2022;37(12):2568\u201385. https:\/\/doi.org\/10.1002\/jbmr.4691.","journal-title":"J Bone Miner Res"},{"key":"3396_CR10","unstructured":"CHMP. ANEXO I Ficha T\u00e9cnica o Resumen de las Caracter\u00edsticas del Producto. Yorvipath."},{"key":"3396_CR11","doi-asserted-by":"crossref","unstructured":"Zelei T, Mendola ND, Elezbawy B, N\u00e9meth B, Campbell JD. Criteria and scoring functions used in multi-criteria decision analysis and value frameworks for the assessment of rare disease therapies: a systematic literature review. Pharmacoecon Open [Internet]. 2021 [cited 2025 Feb 3];5(4):605\u201312. Available from: https:\/\/www.researchgate.net\/publication\/351672607_Criteria_and_Scoring_Functions_Used_in_Multi-criteria_Decision_Analysis_and_Value_Frameworks_for_the_Assessment_of_Rare_Disease_Therapies_A_Systematic_Literature_Review","DOI":"10.1007\/s41669-021-00271-w"},{"key":"3396_CR12","unstructured":"Devlin NJ, Sussex J. Incorporating multiple criteria in HTA-Methods and processes. [cited 2025 Jan 23]; Available from: www.ohe.org"},{"key":"3396_CR13","doi-asserted-by":"crossref","unstructured":"Gilabert-Perramon A, Torrent-Farnell J, Catalan A, Prat A, Fontanet M, Puig-Peir\u00f3 R, et al. Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on Multi-criteria Decision Analysis (MCDA) for orphan drugs. Int J Technol Assess Health Care [Internet]. 2017;33(1):111\u201320. Available from: https:\/\/www.cambridge.org\/core\/product\/identifier\/S0266462317000149\/type\/journal_article","DOI":"10.1017\/S0266462317000149"},{"key":"3396_CR14","doi-asserted-by":"crossref","unstructured":"Badia X, Gil A, Shepherd J. PHP169 - MCDA EVIDEM reference value framework for drug evaluation and decision making in Spain. Value in Health [Internet]. 2018 [cited 2025 Jan 23];21:S179. Available from: http:\/\/www.valueinhealthjournal.com\/article\/S1098301518343651\/fulltext","DOI":"10.1016\/j.jval.2018.09.1063"},{"key":"3396_CR15","unstructured":"Orphan-SEFH. Manual para el desarrollo de un informe de evaluaci\u00f3n de medicamentos hu\u00e9rfanos por parte del grupo ORPHAR-SEFH usando metodolog\u00eda de An\u00e1lisis de Decisi\u00f3n Multicriterio. 2020; Available from: https:\/\/gruposdetrabajo.sefh.es\/orpharsefh\/images\/stories\/documentos\/Manual_MCDA_Orphar_SEFH_060520.pdf"},{"key":"3396_CR16","doi-asserted-by":"crossref","unstructured":"Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making-An introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. [Internet]. 2016 [cited 2025 Jan 29];19(1):1\u201313. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26797229\/","DOI":"10.1016\/j.jval.2015.12.003"},{"key":"3396_CR17","doi-asserted-by":"crossref","unstructured":"Marsh K, Ijzerman M, Thokala P, Baltussen R, Boysen M, Kal\u00f3 Z, et al. Multiple Criteria decision analysis for health care decision making\u2014Emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. [Internet]. 2016 [cited 2025 Jan 29];19(2):125\u201337. Available from: http:\/\/www.valueinhealthjournal.com\/article\/S1098301515300152\/fulltext","DOI":"10.1016\/j.jval.2015.12.016"},{"key":"3396_CR18","doi-asserted-by":"crossref","unstructured":"Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Making [Internet]. 2012 [cited 2025 Jan 24];32(2):376\u201388. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21987539\/","DOI":"10.1177\/0272989X11416870"},{"issue":"7\u20138","key":"3396_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/21678707.2019.1652163","volume":"7","author":"X Badia","year":"2019","unstructured":"Badia X, Chugani D, Abad MR, Arias P, Guill\u00e9n-Navarro E, Jarque I, et al. Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain. Expert Opin Orphan Drugs. 2019;7(7\u20138):363\u201372. https:\/\/doi.org\/10.1080\/21678707.2019.1652163.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"1","key":"3396_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","volume":"38","author":"AA Khan","year":"2023","unstructured":"Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, Gagnon C, et al. Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial. J Bone Min Res. 2023;38(1):14\u201325. https:\/\/doi.org\/10.1002\/jbmr.4726.","journal-title":"J Bone Min Res."},{"key":"3396_CR21","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Diego DA, Badia X, Ben\u00edtez-Hidalgo O, Jim\u00e9nez V, Ju\u00e1rez JC, N\u00fa\u00f1ez R, et al. Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi-criteria decision analysis. Haemophilia [Internet]. 2024[cited 2025 Jan 29];30(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39340327\/","DOI":"10.1111\/hae.15096"},{"key":"3396_CR22","unstructured":"\u00c1lvarez-Rom\u00e1n MT, Cuervo-Arango I, P\u00e9rez-Santamarina R, Poveda JL, Romero JA, Santamar\u00eda A, et al. Determining the value contribution of emicizumab (Hemlibra\u00ae) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Global Reg Health Technol Ass. [Internet]. 2019 [cited 2025 Jan 29];6(1):1\u20138. Available from: https:\/\/www.researchgate.net\/publication\/336331993_Determining_the_value_contribution_of_emicizumab_Hemlibra_R_for_the_prophylaxis_of_haemophilia_A_with_inhibitors_in_Spain_by_multi-criteria_decision_analysis"},{"issue":"1","key":"3396_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40258-022-00770-9","volume":"21","author":"C Domingo","year":"2023","unstructured":"Domingo C, Fernandez M, Garin N, Milara J, Moran I, Muerza I, et al. Determining what represents value in the treatment of refractory or unexplained chronic cough from the perspective of key stakeholders in Spain using multi-criteria decision analysis. Appl Health Econ Health Policy. 2023;21(1):119\u201330. https:\/\/doi.org\/10.1007\/s40258-022-00770-9.","journal-title":"Appl Health Econ Health Policy"},{"key":"3396_CR24","doi-asserted-by":"crossref","unstructured":"Villanueva V, Carre\u00f1o M, Gil-Nagel A, Serrano-Castro PJ, Serratosa JM, Toledo M, et al. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through multi-criteria decision analysis (MCDA). Epilepsy Behav. [Internet]. 2021[cited 2025 Jan 31];122. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34371462\/","DOI":"10.1016\/j.yebeh.2021.108222"},{"issue":"2","key":"3396_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/0272989X11416870","volume":"32","author":"MM Goetghebeur","year":"2012","unstructured":"Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA). Med Decis Making. 2012;32(2):376\u201388. https:\/\/doi.org\/10.1177\/0272989X11416870.","journal-title":"Med Decis Making"},{"issue":"6","key":"3396_CR26","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101(6):2273\u201383. https:\/\/doi.org\/10.1210\/jc.2015-3907.","journal-title":"J Clin Endocrinol Metab"},{"key":"3396_CR27","unstructured":"AEMPS. Informe de Posicionamiento Terap\u00e9utico de palopegteriparatida (Yorvipath\u00ae) en el tratamiento de adultos con hipoparatiroidismo cr\u00f3nico. 2025;"},{"key":"3396_CR28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae693\/7815470","author":"BL Clarke","year":"2024","unstructured":"Clarke BL, Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, et al. Efficacy and Safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial. J Clin Endocrinol Metab. 2024. https:\/\/doi.org\/10.1210\/clinem\/dgae693\/7815470.","journal-title":"J Clin Endocrinol Metab"},{"key":"3396_CR29","doi-asserted-by":"crossref","unstructured":"Gosmanova EO, Houillier P, Rejnmark L, Marelli C, Bilezikian JP. Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review\u202f: Renal disease in chronic hypoparathyroidism. Rev Endocr Metab Disord. [Internet]. 2021 Jun 1 [cited 2025 Jan 31];22(2):297\u2013316. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33599907\/","DOI":"10.1007\/s11154-020-09613-1"},{"key":"3396_CR30","doi-asserted-by":"crossref","unstructured":"Ventosa Vi\u00f1a M, Cu\u00e9llar Olmedo L\u00c1, Crespo Soto C, Palacio Mures JM, Garc\u00eda Duque M, L\u00e1zaro Mart\u00edn L. Actualizaci\u00f3n en el tratamiento del hipoparatiroidismo posquir\u00fargico. Revista ORL, [Internet]. 2022 [cited 2025 Apr 22];13(3):239\u201346. Available from: https:\/\/dialnet.unirioja.es\/servlet\/articulo?codigo=8611113&info=resumen&idioma=ENG","DOI":"10.14201\/orl.27528"},{"issue":"1","key":"3396_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-024-03324-5","volume":"19","author":"X Badia","year":"2024","unstructured":"Badia X, Calleja M\u00c1, Escudero-Vilaplana V, P\u00e9rez-Mart\u00ednez A, Pi\u00f1ana JL, Poveda JL, et al. The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). Orphanet J Rare Dis. 2024;19(1):1\u201313. https:\/\/doi.org\/10.1186\/s13023-024-03324-5.","journal-title":"Orphanet J Rare Dis"},{"key":"3396_CR32","doi-asserted-by":"crossref","unstructured":"Abad M, Gonz\u00e1lez-Meneses A, Gras E, Poveda J, Trillo J, de Vicente D, et al. HTA130 Value contribution of Olipudase Alfa therapy for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) by multi-criteria decision analysis (MCDA). Value Health. [Internet]. 2022 [cited 2025 Jan 30];25(12):S321\u20132. Available from: http:\/\/www.valueinhealthjournal.com\/article\/S1098301522037937\/fulltext","DOI":"10.1016\/j.jval.2022.09.1588"},{"key":"3396_CR33","doi-asserted-by":"crossref","unstructured":"Baltussen R, Niessen L. Cost effectiveness and resource allocation priority setting of health interventions: the need for multi-criteria decision analysis. 2006 [cited 2025 Jan 31]; Available from: http:\/\/www.resource-allocation.com\/content\/4\/1\/14","DOI":"10.2139\/ssrn.945156"},{"issue":"1","key":"3396_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06784-8","volume":"21","author":"D Elvira","year":"2021","unstructured":"Elvira D, Obach M, Pontes C. Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies. BMC Health Serv Res. 2021;21(1):814. https:\/\/doi.org\/10.1186\/s12913-021-06784-8.","journal-title":"BMC Health Serv Res"},{"key":"3396_CR35","unstructured":"Orphar-SEFH grupo. An\u00e1lisis de las evaluaciones MCDA de medicamentos hu\u00e9rfanos en Espa\u00f1a entre el 2018\u20132022 utilizando el marco de medicamentos hu\u00e9rfanos."},{"key":"3396_CR36","doi-asserted-by":"crossref","unstructured":"Drake JI, de Hart JCT, Monle\u00f3n C, Toro W, Valentim J. Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016. J Mark Access Health Policy. [Internet]. 2017 [cited 2025 Sep 9];5(1):1360545. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5645903\/","DOI":"10.1080\/20016689.2017.1360545"},{"issue":"4","key":"3396_CR37","first-page":"208","volume":"46","author":"M\u00c1 Calleja-Hern\u00e1ndez","year":"2022","unstructured":"Calleja-Hern\u00e1ndez M\u00c1, Martinez-Sesmero JM, Vallejo-Aparicio LA, Hern\u00e1ndez-Novoa B, Badia X, Rivero A, et al. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection. Farm Hosp. 2022;46(4):208\u201314.","journal-title":"Farm Hosp"},{"key":"3396_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109350","author":"M Falip","year":"2023","unstructured":"Falip M, L\u00f3pez Gonz\u00e1lez FJ, Mart\u00edn-Herranz I, Merino-Boh\u00f3rquez V, Montoya J, Rey G\u00f3mez-Serranillos I, et al. Value contribution of cenobamate for the treatment of Focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective multi-criteria decision analysis (MCDA). Epilepsy Behav. 2023. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109350.","journal-title":"Epilepsy Behav"},{"key":"3396_CR39","doi-asserted-by":"crossref","unstructured":"Gil-Nagel A, Falip M, S\u00e1nchez-Carpintero R, Abad-Sazatornil MR, Poveda JL, Aibar J\u00c1, et al. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis. Epilepsy Behav. [Internet]. 2022; 132:108711. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022001603","DOI":"10.1016\/j.yebeh.2022.108711"},{"key":"3396_CR40","first-page":"1353","volume":"2022","author":"AM Borobia P\u00e9rez","year":"2022","unstructured":"Borobia P\u00e9rez AM, Gasol M, Paco N, Guarga L, \u00c0ngel Bosch J, Pontes C, et al. Clinical medicine early access to medicines: use of multicriteria decision analysis (MCDA) as a decision tool in Catalonia (Spain). J Clin Med. 2022;2022:1353.","journal-title":"J Clin Med"},{"key":"3396_CR41","doi-asserted-by":"crossref","unstructured":"Takhar P, Geirnaert M, Gavura S, Beca J, Mercer RE, Denburg A, et al. Application of multi-criteria decision analysis (MCDA) to prioritize real-world evidence studies for health technology management: outcomes and lessons learned by the canadian real-world evidence for value of cancer drugs (CanREValue) collaboration. Current Oncol. 2024;[cited 2025 Sep 9];31(4):1876\u201398. Available from: https:\/\/www.mdpi.com\/1718-7729\/31\/4\/141\/htm","DOI":"10.3390\/curroncol31040141"},{"key":"3396_CR42","doi-asserted-by":"crossref","unstructured":"Reyes Abad M, Alerany C, Gonzalez LI, Neth O, Payares-Herrera C, Rodr\u00edguez-Gallego C, et al. Value contribution of leniolisib in the Treatment of Activated PI3K\u03b4 syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA). Global & regional health technology assessment [Internet]. 2025 Jan 27 [cited 2025 Jan 31];12(1):9\u201315. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39882388\/","DOI":"10.33393\/grhta.2025.3199"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03396-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:15Z","timestamp":1763132655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03396-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3396"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03396-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship and\/or publication of this article: Juan Jos\u00e9 D\u00edez has received honoraria for conferences and participation in advisory boards from Ascendis Pharma. Xavier Badia is an employee of Omakase Consulting. Omakase Consulting received funds from Ascendis Pharma for the performance of this study. Reyes Abad has received honoraria for the development of this project from Ascendis Pharma and speakers\u2019 fees from Janssen, CINFA, Astra-Zeneca, Sanofi-Aventis, Novartis. Carmen Alerany has received honoraria for the development of this project from Ascendis Pharma. M\u00f3nica Climente Mart\u00ed has received honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Fresenius-Kabi, Pfizer, Alexion, Kern, Novartis and Roche and honoraria for the development of this project from Ascendis Pharma. Josep Guiu declares personal financial interests in the form of speaking\/travel grants or accommodation from Amgen, AstraZeneca, Bayer, Beigene, Biogen, Boehringer Ingelheim, CSL Bering, F. Hoffmann\u2013La Roche Ltd., Ever Pharma, GlaxoSmithKline, Gilead, Merck Sharp & Dohme, Novartis, Novonordisk, Laphysan, Pierre Fabre, Pfizer, Sandoz, Samsung Bioepis, Sanofi and Takeda and honoraria for the development of this project from Ascendis Pharma. Isabel Mart\u00edn has received honoraria for the development of this project from Ascendis Pharma. Mar\u00eda Caballero is an employee of Omakase Consulting. Omakase Consulting received funds from Ascendis Pharma for the performance of this study. Manuel Mu\u00f1oz Torres has received honoraria for conferences and advisory boards and development of this study from Ascendis Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that no experiments on humans or animals have been carried out for this research. The authors declare that no patient data appear in this article. Full consent to participate in the study and to publish the findings was obtained from all contributors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}